Stoke Therapeutics (STOK) Competitors $9.31 -1.71 (-15.52%) As of 01/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STOK vs. ARWR, PTGX, IOVA, CGON, CNTA, IDYA, TARS, APGE, MIRM, and AKROShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), Iovance Biotherapeutics (IOVA), CG Oncology (CGON), Centessa Pharmaceuticals (CNTA), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Mirum Pharmaceuticals (MIRM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Arrowhead Pharmaceuticals Protagonist Therapeutics Iovance Biotherapeutics CG Oncology Centessa Pharmaceuticals IDEAYA Biosciences Tarsus Pharmaceuticals Apogee Therapeutics Mirum Pharmaceuticals Akero Therapeutics Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership. Do analysts recommend ARWR or STOK? Arrowhead Pharmaceuticals presently has a consensus price target of $43.33, suggesting a potential upside of 122.56%. Stoke Therapeutics has a consensus price target of $21.29, suggesting a potential upside of 130.12%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Stoke Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor ARWR or STOK? In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Stoke Therapeutics. MarketBeat recorded 16 mentions for Arrowhead Pharmaceuticals and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.42 beat Arrowhead Pharmaceuticals' score of 1.16 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ARWR or STOK more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. Stoke Therapeutics' return on equity of -54.45% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -182.69% -64.04% Stoke Therapeutics -629.90%-54.45%-40.77% Do insiders & institutionals have more ownership in ARWR or STOK? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 11.3% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ARWR or STOK? Arrowhead Pharmaceuticals received 434 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 74.83% of users gave Stoke Therapeutics an outperform vote while only 65.31% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArrowhead PharmaceuticalsOutperform Votes54465.31% Underperform Votes28934.69% Stoke TherapeuticsOutperform Votes11074.83% Underperform Votes3725.17% Which has more volatility and risk, ARWR or STOK? Arrowhead Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Which has better valuation and earnings, ARWR or STOK? Stoke Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M682.27-$599.49M-$5.02-3.88Stoke Therapeutics$16.74M29.26-$104.70M-$2.10-4.40 SummaryStoke Therapeutics beats Arrowhead Pharmaceuticals on 12 of the 19 factors compared between the two stocks. Ad Behind the MarketsElon Musk: my AI will be “worth more than Tesla”Tesla made Elon Musk the richest man in human history. And now, Elon's got a new AI project...Get all the details here >>> Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$489.95M$6.62B$5.24B$9.04BDividend YieldN/A2.91%5.30%4.19%P/E Ratio-4.4010.5387.8517.27Price / Sales29.26222.291,103.87145.76Price / CashN/A57.1143.3337.88Price / Book2.595.195.185.13Net Income-$104.70M$153.18M$121.58M$227.03M7 Day Performance-16.14%5.89%4.97%3.69%1 Month Performance-30.29%0.74%21.19%4.61%1 Year Performance75.86%5.81%32.08%20.92% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics4.3066 of 5 stars$9.31-15.5%$21.29+128.6%+77.0%$493.12M$16.74M-4.43100News CoveragePositive NewsGap DownHigh Trading VolumeARWRArrowhead Pharmaceuticals4.4893 of 5 stars$18.64-1.7%$42.70+129.1%-44.7%$2.32B$3.55M-3.71400Insider TradeAnalyst RevisionPositive NewsPTGXProtagonist Therapeutics2.1703 of 5 stars$38.59-0.9%$53.78+39.4%+76.5%$2.30B$323.80M14.51125IOVAIovance Biotherapeutics3.9845 of 5 stars$7.23-1.9%$23.00+218.1%-12.6%$2.20B$90.86M-4.85500CGONCG Oncology2.4634 of 5 stars$28.70-4.5%$63.88+122.6%N/A$2.18B$684,000.000.0061Analyst ForecastNews CoveragePositive NewsGap UpCNTACentessa Pharmaceuticals3.2306 of 5 stars$16.49-2.7%$25.83+56.7%+157.4%$2.17B$6.85M-10.7872Analyst ForecastGap DownIDYAIDEAYA Biosciences4.1436 of 5 stars$24.88-1.1%$53.67+115.7%-25.9%$2.15B$23.39M-10.6880TARSTarsus Pharmaceuticals0.4226 of 5 stars$55.64+1.2%$54.20-2.6%+180.9%$2.13B$129.62M-14.6050APGEApogee Therapeutics2.7779 of 5 stars$44.68-2.5%$89.71+100.8%+79.9%$2.01BN/A-18.4691Positive NewsMIRMMirum Pharmaceuticals3.5644 of 5 stars$41.32-0.6%$57.10+38.2%+45.8%$1.98B$307.03M-20.46140AKROAkero Therapeutics3.7241 of 5 stars$27.87-1.3%$46.83+68.0%+16.5%$1.95BN/A-7.4330Insider Trade Related Companies and Tools Related Companies ARWR Alternatives PTGX Alternatives IOVA Alternatives CGON Alternatives CNTA Alternatives IDYA Alternatives TARS Alternatives APGE Alternatives MIRM Alternatives AKRO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STOK) was last updated on 1/8/2025 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDonald Trump to Repeal Executive Order #14110?Nvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this Stock before Trump Takes Office!We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. ...Behind the Markets | SponsoredMy #1 Crypto of 2025 – “Crypto Royalties”Man Who Recommended Bitcoin at $600 – Reveals: “Crypto Royalties” My #1 Crypto Play for 2025 and Beyond… It...Centurion Publishing | SponsoredFrom bankrupt to delivering 610,000% returnsWalk the empty streets of this barren town and you would have no idea that behind the sand-scarred blight is o...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
